Head to Head Contrast: ProKidney (NASDAQ:PROK) & Lotus Pharmaceuticals (OTCMKTS:LTUS)

ProKidney (NASDAQ:PROK) and Lotus Pharmaceuticals (OTCMKTS:LTUS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares ProKidney and Lotus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	-7,725.20%	N/A	-18.83%
Lotus Pharmaceuticals	N/A	N/A	N/A

Institutional & Insider Ownership

51.6% of ProKidney shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares ProKidney and Lotus Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$893,000.00	628.85	-$68.99 million	($0.52)	-3.58
Lotus Pharmaceuticals	N/A	N/A	-$30,000.00	N/A	N/A

Lotus Pharmaceuticals has lower revenue, but higher earnings than ProKidney.

Risk & Volatility

ProKidney has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of -1.69, meaning that its stock price is 269% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for ProKidney and Lotus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2	1	4	1	2.50
Lotus Pharmaceuticals	0	0	0	0	0.00

ProKidney currently has a consensus price target of $7.40, indicating a potential upside of 297.85%. Given ProKidney’s stronger consensus rating and higher possible upside, equities research analysts plainly believe ProKidney is more favorable than Lotus Pharmaceuticals.

Summary

ProKidney beats Lotus Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About Lotus Pharmaceuticals

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.